Timing of onset of cognitive decline: results from Whitehall II prospective cohort study.

Institut National de la Santé et de la Recherche Médicale, U1018, Centre for Research in Epidemiology and Population Health, Hôpital Paul Brousse, 94807 Villejuif Cedex, France.
BMJ (online) (Impact Factor: 16.38). 01/2012; 344:d7622. DOI: 10.1136/bmj.d7622
Source: PubMed

ABSTRACT To estimate 10 year decline in cognitive function from longitudinal data in a middle aged cohort and to examine whether age cohorts can be compared with cross sectional data to infer the effect of age on cognitive decline.
Prospective cohort study. At study inception in 1985-8, there were 10,308 participants, representing a recruitment rate of 73%.
Civil service departments in London, United Kingdom.
5198 men and 2192 women, aged 45-70 at the beginning of cognitive testing in 1997-9.
Tests of memory, reasoning, vocabulary, and phonemic and semantic fluency, assessed three times over 10 years.
All cognitive scores, except vocabulary, declined in all five age categories (age 45-49, 50-54, 55-59, 60-64, and 65-70 at baseline), with evidence of faster decline in older people. In men, the 10 year decline, shown as change/range of test × 100, in reasoning was -3.6% (95% confidence interval -4.1% to -3.0%) in those aged 45-49 at baseline and -9.6% (-10.6% to -8.6%) in those aged 65-70. In women, the corresponding decline was -3.6% (-4.6% to -2.7%) and -7.4% (-9.1% to -5.7%). Comparisons of longitudinal and cross sectional effects of age suggest that the latter overestimate decline in women because of cohort differences in education. For example, in women aged 45-49 the longitudinal analysis showed reasoning to have declined by -3.6% (-4.5% to -2.8%) but the cross sectional effects suggested a decline of -11.4% (-14.0% to -8.9%).
Cognitive decline is already evident in middle age (age 45-49).

  • [Show abstract] [Hide abstract]
    ABSTRACT: A decade following the paradigm-shifting concept that endogenous forms of soluble, non-fibrillar amyloid-β (Aβ) might constitute the major bioactive entity causing synaptic loss and cognitive decline in Alzheimer's disease (AD), our understanding of these oligomeric species still remains conspicuously superficial. The current lack of direct evaluation tools for each endogenous Aβ oligomer hampers our ability to readily address crucial question such as: (i) where they form and accumulate?; (ii) when they first appear in human brains and body fluids?; (iii) what is the longitudinal expression of these putative toxins during the course of the disease?; (iv) and how do these soluble Aβ assemblies alter synaptic and neuronal function in the brain? Despite these limitations, indirect ex vivo measurement and isolation from biological specimens has been possible and have allowed parsing out intrinsic differences between putative endogenous Aβ oligomers. In this review, I integrated recent findings and extrapolated emerging hypotheses derived from these studies with the hope to provide a clarified view on the putative role of endogenous Aβ oligomers in AD, with a particular emphasis on the timing at which these soluble species might act in the aging and diseased brain.
    Swiss medical weekly: official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 01/2014; 144:w14021. · 1.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: These authors have contributed equally to this work. Executive function declines with age, but engaging in aerobic exercise may attenuate decline. One mechanism by which aerobic exercise may preserve executive function is through the up-regulation of brain-derived neurotropic factor (BDNF), which also declines with age. The present study examined BDNF as a mediator of the effects of a 1-year walking intervention on executive function in 90 older adults (mean age = 66.82). Participants were randomized to a stretching and toning control group or a moderate intensity walking intervention group. BDNF serum levels and performance on a task-switching paradigm were collected at baseline and follow-up. We found that age moderated the effect of intervention group on changes in BDNF levels, with those in the highest age quartile showing the greatest increase in BDNF after 1-year of moderate intensity walking exercise (p = 0.036). The mediation analyses revealed that BDNF mediated the effect of the intervention on task-switch accuracy, but did so as a function of age, such that exercise-induced changes in BDNF mediated the effect of exercise on task-switch performance only for individuals over the age of 71. These results demonstrate that both age and BDNF serum levels are important factors to consider when investigating the mechanisms by which exercise interventions influence cognitive outcomes, particularly in elderly populations.
    Frontiers in human neuroscience. 12/2014; 8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Au cours de ces 20 dernières années, les connaissances concernant la maladie d’Alzheimer se sont accumulées, améliorant sa compréhension, mais, malgré un effort de recherche considérable, elles n’aboutissent pas actuellement à un véritable traitement. Des travaux récents en alzheimérologie mettent en évidence plusieurs propriétés de la matière vivante (plasticité, réactivité, réversibilité, activité à très petites doses de substances en cause dans la maladie, inversion d’action selon la dose, etc.) sur lesquelles s’appuie l’homéopathie, ce qui incite à examiner la contribution possible de celle-ci. En particulier, le procédé hahnemannien de dilution-succussion, en permettant de cibler de manière très sélective et aux déconcentrations appropriées les substances en cause dans le processus physiopathologique de la maladie, ouvre une voie prometteuse pour la recherche et le traitement de la maladie d’Alzheimer.
    Revue d'Homeopathie 09/2012; 3(3):80-87.

Full-text (2 Sources)

Available from
Jun 4, 2014

Archana Singh-Manoux